NiN Healthcare

NiN Healthcare is a Danish biotechnology company focused on the discovery and development of next-generation peptide therapeutics for metabolic diseases, particularly obesity and type 2 diabetes. The company was founded in 2023 by a team of former Novo Nordisk R&D executives who were instrumental in the development of modern GLP-1 therapies. NiN Healthcare utilizes its "Next-in-Nature" (NiN) platform to identify and optimize naturally occurring peptides to create multi-agonist treatments with improved efficacy and tolerability profiles. Currently in the pre-clinical stage, the company aims to address the global metabolic health crisis by leveraging deep expertise in peptide chemistry and metabolic biology. Backed by Novo Holdings, NiN Healthcare is positioned as a significant emerging player in the competitive incretin-based therapy landscape.